The role of perioperative chemotherapy in patients with resectable colorectal liver metastases;Intérêt de la chimiothérapie péri- opératoire dans la prise en charge des métastases hépatiques résécables d'origine colorectale

Journal de Chirurgie

Volumn 147, Issue SUPPL.1, 2010, Pages

  Brouquet, A ^a,b   Mitry, E ^a,b   Benoist, S ^a,b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; COLON TUMOR; HUMAN; LIVER TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; RECTUM TUMOR; RISK FACTOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECTAL NEOPLASMS; RISK FACTORS;

EID: 77951138195     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(10)70001-6     Document Type: Article

References (35)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors infl uencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-1410
3. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23:2038-2048
4. Scheele J. Hepatectomy for liver metastases. Br J Surg 1993; 80:274-276
5. Nordlinger B, Jaeck D, Guiguet M, Vaillant JC, Balladur P, Schaal JC. Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordlinger B, Jaeck D, editors. Treatment of hepatic metastases of colorectal cancer. Paris: Springer-Verlag; 1992. pp. 129-136
6. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1,001 consecutive cases. Ann Surg 1999;230:309-318
7. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005;23:8490-8499
8. Lorenz M, Müller HH, Schramm H, Gassel HJ, Rau HG, Ridwelski K, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases. Ann Surg 1998;228:756-762
9. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-2048
10. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy- an intergroup study. J Clin Oncol 2002;20:1499-1505
11. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-4982
12. Langer B, Bleiberg H, Labianca R. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. J Clin Oncol 2002;20:149a (abstr 592).
13. Mitry E, Fields A, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008;26:4906-4911
14. Ychou M, Hohenberger W, Thezenas S, Navarro M, Gascón P, Bokemeyer C, et al. Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU irinotecan (LV5FU IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (CPTGMA- 301). J Clin Oncol 2008;26:LBA4013.
15. Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963-969 (Pubitemid 37026325)
16. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109-115
17. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-1061
18. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004;15:460-466
19. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034-1044
20. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-853
21. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, at al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7. (Pubitemid 43054046)
22. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90 days mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072
23. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006;24:4983-4990
24. Nordlinger B, Benoist S. Benefi ts and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006;24:4954-4955
25. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard- Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008;24:118-124
26. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939-3945
27. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016
28. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299-304.
29. Adam R, Wicherts DA, De Haas RJ, Aloia T, Lévi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008;26:1635-1641
30. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26:5344-5351
31. Wein A, Riedel C, Brückl W, Merkel S, Ott R, Hanke B, et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003;64;131-138 (Pubitemid 36173378)
32. Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005;23:502-509
33. Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009;16:1208-1211
34. Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, et al. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009;16:1844-1851
35. Reddy SK, Zorzi D, Lum YW, Barbas AS, Pawlik TM, Ribero D, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: A retrospective multi-institutional analysis. Ann Surg Oncol 2009;16:1809-1819